Capital Analysts, LLC Eli Lilly & CO Transaction History

Capital Analysts, LLC

$2.49 Billion
Q4 2024

A detailed history of Capital Analysts, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Capital Analysts, LLC holds 3,557 shares of LLY stock, worth $3.25 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

3,557

Previous 2,686 32.43%

Holding current value

$3.25 Million

Previous $2.38 Million 15.38%

% of portfolio

0.11%

Previous 0.1%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$727.2 - $932.06 $633,391 - $811,824	871 Added 32.43%	3,557 $2.75 Million
Q3 2024 Nov 13, 2024	BUY	$772.14 - $960.02 $1.26 Million - $1.56 Million	1,626 Added 153.4%	2,686 $2.38 Million
Q2 2024 Aug 14, 2024	BUY	$724.87 - $909.04 $11,597 - $14,544	16 Added 1.53%	1,060 $960,000
Q1 2024 May 14, 2024	SELL	$592.2 - $792.28 $23,688 - $31,691	-40 Reduced 3.69%	1,044 $812,000
Q4 2023 Jan 30, 2024	SELL	$525.19 - $619.13 $20,482 - $24,146	-39 Reduced 3.47%	1,084 $632,000
Q3 2023 Nov 13, 2023	BUY	$434.7 - $599.3 $33,906 - $46,745	78 Added 7.46%	1,123 $603,000
Q2 2023 Aug 11, 2023	BUY	$350.74 - $468.98 $246,570 - $329,692	703 Added 205.56%	1,045 $490,000
Q1 2023 May 05, 2023	BUY	$310.63 - $364.82 $13,357 - $15,687	43 Added 14.38%	342 $117,000
Q4 2022 Feb 08, 2023	SELL	$321.55 - $374.67 $3,537 - $4,121	-11 Reduced 3.55%	299 $109,000
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $8,004 - $9,122	27 Added 9.54%	310 $100,000
Q3 2021 Nov 04, 2021	SELL	$221.6 - $272.71 $1,772 - $2,181	-8 Reduced 2.75%	283 $65,000
Q2 2021 Nov 15, 2021	SELL	$180.55 - $233.54 $269,561 - $348,675	-1,493 Reduced 83.69%	291 $67,000
Q2 2021 Aug 05, 2021	BUY	$180.55 - $233.54 $269,741 - $348,908	1,494 Added 515.17%	1,784 $409,000
Q1 2021 May 17, 2021	BUY	$164.32 - $212.72 $9,201 - $11,912	56 Added 23.93%	290 $55,000
Q4 2020 Feb 16, 2021	SELL	$130.46 - $172.63 $260 - $345	-2 Reduced 0.85%	234 $40,000
Q1 2020 May 08, 2020	SELL	$119.05 - $147.35 $19,167 - $23,723	-161 Reduced 40.55%	236 $33,000
Q1 2019 May 13, 2019	BUY	$111.31 - $131.02 $12,355 - $14,543	111 Added 38.81%	397 $51,000
Q4 2018 Feb 13, 2019	SELL	$105.9 - $118.64 $2,223 - $2,491	-21 Reduced 6.84%	286 $33,000
Q2 2018 Aug 03, 2018	SELL	$75.7 - $86.88 $19,379 - $22,241	-256 Reduced 45.47%	307 $0
Q1 2018 May 14, 2018	BUY	$74.21 - $87.6 $16,177 - $19,096	218 Added 63.19%	563 $44,000
Q4 2017 Feb 14, 2018	SELL	$81.94 - $87.89 $573 - $615	-7 Reduced 1.99%	345 $29,000
Q4 2017 Feb 12, 2018	SELL	$81.94 - $87.89 $7,046 - $7,558	-86 Reduced 19.63%	352 $3,000
Q3 2017 Nov 06, 2017	BUY	$77.07 - $85.54 $33,756 - $37,466	438	438 $38,000

Others Institutions Holding LLY

# of Institutions

4,272

Shares Held

757M

Call Options Held

10.2M

Put Options Held

11.4M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $869B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Analysts, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Analysts, LLC with notifications on news.

Account

Capital Analysts, LLC Eli Lilly & CO Transaction History